Division of General Surgery, Dalhousie University, Halifax, Canada.
Division of Thoracic Surgery, Dalhousie University, Halifax, Canada.
Surg Endosc. 2017 Oct;31(10):4211-4216. doi: 10.1007/s00464-017-5479-z. Epub 2017 Mar 24.
Esophagectomy has been the standard of care for patients with intramucosal adenocarcinoma (IMC) in the setting of Barrett's esophagus. It is, however, associated with significant post-operative morbidity and mortality. Endoscopic mucosal resection (EMR) offers a minimally invasive approach with lesser morbidity. This study investigates the transition from esophagectomy to EMR for IMC with respect to eradication rates, post-operative morbidity, and long-term survival.
Patients diagnosed with IMC from 2005 to 2013 were identified retrospectively. Beginning in 2009, preferred initial therapy for IMC transitioned from esophagectomy to EMR. Esophagectomy was performed either through a transthoracic or transhiatal technique. EMR was repeated until resolution of IMC on pathology or progression of disease. Continuous data are expressed as mean (SD) and analyzed using Student's t test. Categorical data are presented as number (%) and analyzed using Fisher's exact test.
We identified 23 patients; 12 patients underwent esophagectomy and 11 patients underwent EMR as initial therapy. Patients were similar with respects to age, gender, and comorbidity index. Most tumors arose from short segment (vs long segment) Barrett's (esophagectomy: 9 (75%) vs. EMR: 10 (91%), p = 0.59) and one patient in each group had superficial invasion into the submucosa (T1sm1), the remainder having mucosal disease. Esophagectomy was associated with 7 (58%) minor complications and 2 (17%) major complications (respiratory failure, anastomotic leak), whereas there were no complications related to EMR (p < 0.01). EMR successfully eradicated IMC in 10 patients (91%) with one progressing to esophagectomy. Patients required 2 (1) endoscopies to achieve eradication. There was one mortality in each group on long-term follow-up (log-rank test, p = 0.62).
EMR was successful in eradicating IMC in 10/11 patients with similar long-term recurrence and mortality to esophagectomy patients. Patients with IMC may benefit from EMR as initial therapy by obviating the need for a complex and morbid operation.
对于 Barrett 食管中黏膜内腺癌(IMC)患者,食管切除术一直是标准的治疗方法。然而,它与显著的术后发病率和死亡率相关。内镜黏膜切除术(EMR)提供了一种微创方法,发病率较低。本研究旨在探讨 IMC 从食管切除术向 EMR 过渡的情况,包括根除率、术后发病率和长期生存率。
回顾性地确定了 2005 年至 2013 年期间被诊断为 IMC 的患者。从 2009 年开始,IMC 的初始治疗首选从食管切除术改为 EMR。食管切除术通过经胸或经食管裂孔技术进行。EMR 重复进行,直到病理检查或疾病进展时 IMC 得到解决。连续数据表示为平均值(标准差),并使用学生 t 检验进行分析。分类数据表示为数量(%),并使用 Fisher 精确检验进行分析。
我们共确定了 23 例患者;12 例患者接受了食管切除术,11 例患者接受了 EMR 作为初始治疗。患者在年龄、性别和合并症指数方面相似。大多数肿瘤来自短节段(食管切除术:9(75%)vs. EMR:10(91%),p=0.59) Barrett 食管,每组各有 1 例患者黏膜下浅层浸润(T1sm1),其余患者为黏膜疾病。食管切除术有 7 例(58%)轻微并发症和 2 例(17%)严重并发症(呼吸衰竭,吻合口漏),而 EMR 无相关并发症(p<0.01)。EMR 成功根除了 10 例(91%)患者的 IMC,其中 1 例进展为食管切除术。患者需要 2(1)次内镜检查才能达到根除效果。在长期随访中,每组各有 1 例死亡(对数秩检验,p=0.62)。
EMR 成功根除了 11 例 IMC 患者中的 10 例,其长期复发率和死亡率与食管切除术患者相似。IMC 患者可能受益于 EMR 作为初始治疗,避免了复杂和严重的手术。